Barclays’s Guardant Health GH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23.5M | Sell |
253,959
-82,315
| -24% | -$8.26M | 0.01% | 1027 |
|
|
2025
Q4 | $34.3M | Buy |
336,274
+58,838
| +21% | +$5.26M | 0.01% | 959 |
|
|
2025
Q3 | $17.3M | Sell |
277,436
-118,544
| -30% | -$6.45M | ﹤0.01% | 1304 |
|
|
2025
Q2 | $20.6M | Buy |
395,980
+152,642
| +63% | +$6.82M | ﹤0.01% | 1114 |
|
|
2025
Q1 | $10.4M | Sell |
243,338
-127,556
| -34% | -$5.5M | ﹤0.01% | 1376 |
|
|
2024
Q4 | $11.3M | Sell |
370,894
-516,137
| -58% | -$14.5M | ﹤0.01% | 1482 |
|
|
2024
Q3 | $20.3M | Buy |
887,031
+409,659
| +86% | +$11.6M | 0.01% | 1057 |
|
|
2024
Q2 | $13.8M | Sell |
477,372
-417,468
| -47% | -$9.72M | ﹤0.01% | 1066 |
|
|
2024
Q1 | $18.5M | Buy |
894,840
+464,085
| +108% | +$9.95M | 0.01% | 1030 |
|
|
2023
Q4 | $11.7M | Buy |
430,755
+154,656
| +56% | +$4.06M | ﹤0.01% | 1400 |
|
|
2023
Q3 | $8.18M | Buy |
276,099
+73,227
| +36% | +$2.57M | 0.01% | 1080 |
|
|
2023
Q2 | $7.26M | Buy |
202,872
+50,428
| +33% | +$1.45M | ﹤0.01% | 1136 |
|
|
2023
Q1 | $3.57M | Buy |
152,444
+8,112
| +6% | +$232K | ﹤0.01% | 1774 |
|
|
2022
Q4 | $3.93M | Sell |
144,332
-33,317
| -19% | -$1.52M | ﹤0.01% | 1789 |
|
|
2022
Q3 | $9.56M | Buy |
177,649
+16,443
| +10% | +$844K | 0.01% | 873 |
|
|
2022
Q2 | $6.5M | Sell |
161,206
-45,346
| -22% | -$2.25M | ﹤0.01% | 1199 |
|
|
2022
Q1 | $13.7M | Buy |
206,552
+17,778
| +9% | +$1.22M | 0.01% | 812 |
|
|
2021
Q4 | $18.9M | Sell |
188,774
-4,180
| -2% | -$432K | 0.01% | 966 |
|
|
2021
Q3 | $24.1M | Sell |
192,954
-46,063
| -19% | -$5.47M | 0.01% | 811 |
|
|
2021
Q2 | $29.7M | Buy |
239,017
+53,680
| +29% | +$7.22M | 0.01% | 713 |
|
|
2021
Q1 | $28.3M | Sell |
185,337
-9,760
| -5% | -$1.48M | 0.02% | 659 |
|
|
2020
Q4 | $25.1M | Buy |
195,097
+194,547
| +35,372% | +$22.4M | 0.01% | 736 |
|
|
2020
Q3 | $61K | Buy |
550
+335
| +156% | +$30.6K | ﹤0.01% | 4499 |
|
|
2020
Q2 | $17K | Sell |
215
-7,285
| -97% | -$587K | ﹤0.01% | 5231 |
|
|
2020
Q1 | $522K | Sell |
7,500
-162,722
| -96% | -$12.5M | ﹤0.01% | 3543 |
|
|
2019
Q4 | $13.3M | Buy |
170,222
+74,567
| +78% | +$5.37M | 0.01% | 1200 |
|
|
2019
Q3 | $6.11M | Buy |
95,655
+77,245
| +420% | +$6.81M | ﹤0.01% | 1675 |
|
|
2019
Q2 | $1.59M | Sell |
18,410
-12,227
| -40% | -$934K | ﹤0.01% | 3174 |
|
|
2019
Q1 | $2.35M | Buy |
30,637
+12,962
| +73% | +$719K | ﹤0.01% | 2392 |
|
|
2018
Q4 | $664K | Buy |
+17,675
| New | +$651K | ﹤0.01% | 3540 |
|
Other funds holding GH
VPM
VCM
Barclays's GH Position: Q1 2026 in Review
Barclays reduced its Guardant Health (GH) stake by 24% in Q1 2026, selling an estimated $8.26M and leaving 253,959 shares worth $23.5M. The position accounts for 0.01% of the portfolio, ranked #1027.
Barclays first reported a position in GH in Q4 2018 and has held it in 30 quarters since. The position peaked at $34.3M in Q4 2025. 483 funds tracked by Wall St. Rank hold GH as of Q1 2026.
- Barclays held 253,959 shares of Guardant Health worth $23.5M as of Q1 2026.
- Barclays sold 82,315 Guardant Health shares in Q1 2026, an estimated $8.26M.
- Guardant Health made up 0.01% of Barclays's portfolio in Q1 2026, its #1027 holding.
- Barclays first reported a position in Guardant Health in Q4 2018 and has held it in 30 quarters since.
- Barclays's Guardant Health position peaked at $34.3M in Q4 2025.
- 483 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.